Document:

<PAGE>

                                                                   EXHIBIT 10.18

                               SECURITY AGREEMENT

     This Security Agreement is made as of May 16, 2001 between Curon Medical,
Inc., a Delaware corporation ("Pledgee"), and Jim Goode ("Pledgor").

     1.  Note Issuance. Pledgee has agreed to lend Pledgor $68,500 pursuant to a
         -------------
promissory note (the "Note"). The Note and the obligations thereunder are as set
forth in Exhibit A to this Security Agreement.
         ---------

     2.  Creation and Description of Security Interest.  Pledgor, pursuant to
         ---------------------------------------------
the California Commercial Code, hereby pledges thirty thousand (30,000) shares
of the Common Stock of Oratec Interventions, Inc., a Delaware corporation
(herein sometimes referred to as the "Collateral" or the "Pledged Stock") and
shall deliver said certificate to the Secretary of Pledgee ("Pledgeholder")
within 30 days herein, who shall hold said certificate subject to the terms and
conditions of this Security Agreement.

     The pledged stock (together with an executed blank stock assignment
attached hereto as Exhibit B for use in transferring all or a portion of the
                   ---------
Shares to Pledgee if, as and when required pursuant to this Security Agreement)
shall be held by the Pledgeholder as security for the repayment of the Note, and
any extensions or renewals thereof, and the Pledgeholder shall not encumber or
dispose of such Shares except in accordance with the provisions of this Security
Agreement.

     3.  Pledgor's Representations and Covenants.  To induce Pledgee to enter
         ---------------------------------------
into this Security Agreement, Pledgor represents and covenants to Pledgee, its
successors and assigns, as follows:

         (a)  Payment of Indebtedness.  Pledgor will pay the principal sum of
              -----------------------
the Note secured hereby, together with interest thereon, at the time and in the
manner provided in the Note.

         (b)  Encumbrances.  The Shares are free of all other encumbrances,
              ------------
defenses and liens, and Pledgor will not further encumber the Shares without the
prior written consent of Pledgee.

         (c)  Margin Regulations.  In the event that Pledgee's Common Stock is
              ------------------
now or later becomes margin-listed by the Federal Reserve Board and Pledgee is
classified as a "lender" within the meaning of the regulations under Part 207 of
Title 12 of the Code of Federal Regulations ("Regulation G"), Pledgor agrees to
cooperate with Pledgee in making any amendments to the Note or providing any
additional collateral as may be necessary to comply with such regulations.

     4.  Voting Rights.  During the term of this pledge and so long as all
         -------------
payments of principal and interest are made as they become due under the terms
of the Note, Pledgor shall have the right to vote all of the Shares pledged
hereunder.

     5.  Stock Adjustments.  In the event that during the term of the pledge any
         -----------------
stock dividend, reclassification, readjustment or other changes are declared or
made in the capital structure of Pledgee, all new, substituted and additional
shares or other securities issued by reason of any such change shall be
delivered to and held by the Pledgee under the terms of this Security Agreement
in
<PAGE>

the same manner as the Shares originally pledged hereunder. In the event of
substitution of such securities, Pledgor, Pledgee and Pledgeholder shall
cooperate and execute such documents as are reasonable so as to provide for the
substitution of such Collateral and, upon such substitution, references to
"Shares" in this Security Agreement shall include the substituted shares of
capital stock of Pledgor as a result thereof.

     6.   Default.  Pledgor shall be deemed to be in default of the Note and of
          -------
this Security Agreement in the event that payment of principal or interest on
the Note shall be delinquent for a period of 30 days or more. In the case of
default, Pledgee shall have the right to accelerate payment of the Note upon
notice to Pledgor, and Pledgee shall thereafter be entitled to pursue its
remedies under the California Commercial Code.

     7.   Release of Collateral.  Subject to any applicable contrary rules under
          ---------------------
Regulation G, there shall be released from this pledge a portion of the Pledged
Shares held by Pledgeholder hereunder upon payments of the principal of the
Note.  The number of the Pledged Shares which shall be released shall be that
number of full shares which bears the same proportion to the initial number of
shares pledged hereunder as the payment of principal bears to the initial full
principal amount of the Note.

     8.   Withdrawal or Substitution of Collateral.  Pledgor shall not sell,
          ----------------------------------------
withdraw, pledge, substitute or otherwise dispose of all or any part of the
Collateral without the prior written consent of Pledgee.

     9.   Term.  The within pledge of Shares shall continue until the payment of
          ----
all indebtedness secured hereby, at which time the remaining pledged stock shall
be promptly delivered to Pledgor, subject to the provisions for prior release of
a portion of the Collateral as provided in paragraph 7 above.

     10.  Insolvency.  Pledgor agrees that if a bankruptcy or insolvency
          ----------
proceeding is instituted by or against it, or if a receiver is appointed for the
property of Pledgor, or if Pledgor makes an assignment for the benefit of
creditors, the entire amount unpaid on the Note shall become immediately due and
payable, and Pledgee may proceed as provided in the case of default.

     11.  Pledgeholder Liability.  In the absence of willful or gross
          ----------------------
negligence, Pledgeholder shall not be liable to any party for any of his acts,
or omissions to act, as Pledgeholder.

     12.  Invalidity of Particular Provisions.  Pledgor and Pledgee agree that
          -----------------------------------
the enforceability or invalidity of any provision or provisions of this Security
Agreement shall not render any other provision or provisions herein contained
unenforceable or invalid.

     13.  Successors or Assigns.  Pledgor and Pledgee agree that all of the
          ---------------------
terms of this Security Agreement shall be binding on their respective successors
and assigns, and that the term "Pledgor" and the term "Pledgee" as used herein
shall be deemed to include, for all purposes, the respective designees,
successors, assigns, heirs, executors and administrators.

     14.  Governing Law.  This Security Agreement shall be interpreted and
          -------------
governed under the internal substantive laws, but not the choice of law rules,
of California.

                                      -2-
<PAGE>

     IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of
the day and year first above written.

PLEDGOR                               /s/  Jim Goode
                                      --------------------------------------
                                      Jim Goode

                                      Address:   9073 Cedar Ridge Drive
                                                 Granite Bay, CA  95746

PLEDGEE                               CURON MEDICAL, INC.
                                      a Delaware corporation

                                      /s/ John W. Morgan
                                      --------------------------------------
                                      John W. Morgan, President and CEO

PLEDGEHOLDER                          /s/ David J. Saul
                                      ----------------------
                                      David J. Saul

                                      Address:  Wilson Sonsini Goodrich & Rosati
                                                650 Page Mill Road
                                                Palo Alto, CA 94304

                                      -3-
<PAGE>

                                   EXHIBIT A
                                   ---------

                                      NOTE

$68,500.00                                                 Sunnyvale, California
                                                                    May 16, 2001

     FOR VALUE RECEIVED, Jim Goode, promises to pay to Curon Medical, Inc., a
Delaware corporation (the "Company"), or order, the principal sum of Sixty-eight
Thousand Five Hundred dollars ($68,500), together with interest on the unpaid
principal hereof from the date hereof at the rate of four point eight percent
(4.8 %) per annum, compounded semi-annually.

     Principal and interest shall be due and payable on May 16, 2002.   Payment
of principal and interest shall be made in lawful money of the United States of
America.

     The undersigned may at any time prepay all or any portion of the principal
or interest owing hereunder.

     This Note is secured in part by a pledge of thirty thousand (30,000) shares
of the Common Stock of Oratec Interventions, Inc. that have a total value as of
the date of this note of at least One Hundred and Thirty-nine Thousand dollars
($139,000) under the terms of a Security Agreement of even date herewith and is
subject to all the provisions thereof.

     The holder of this Note shall have full recourse against the undersigned,
and shall not be required to proceed against the above collateral securing this
Note in the event of default.

     In the event the undersigned shall cease to be an employee or consultant of
the Company for any reason, this Note shall, at the option of the Company, be
accelerated, and the whole unpaid balance on this Note of principal and accrued
interest shall be immediately due and payable.

     Should any action be instituted for the collection of this Note, the
reasonable costs and attorneys' fees therein of the holder shall be paid by the
undersigned.

                                            /s/ Jim Goode
                                            ____________________________________
                                            Jim Goode
<PAGE>

                                   EXHIBIT B
                                   ---------

                      ASSIGNMENT SEPARATE FROM CERTIFICATE

     FOR VALUE RECEIVED I, Jim Goode ("Pledgor"), hereby sell, assign and
transfer unto Curon Medical, Inc. ("Pledgee") thirty thousand (30,000) shares of
the Common Stock of Oratec Interventions, Inc. standing in my name of the books
of said corporation represented by Certificate No. _____ herewith and do hereby
irrevocably constitute and appoint __________________________________ to
transfer the said stock on the books of the within named corporation with full
power of substitution in the premises.

     This Stock Assignment may be used only in accordance with the Security
Agreement between Curon Medical, Inc. and the undersigned dated May 16, 2001.

Dated: _______________, ____

                                           Signature: /s/ Jim Goode
                                                     ________________________

INSTRUCTIONS: Please do not fill in any blanks other than the signature line.
The purpose of this assignment is to enable the Pledgee to exercise its rights
to the Collateral as set forth in the Security Agreement, without requiring
additional signatures on the part of the Pledgor.<PAGE>

                                                                   EXHIBIT 10.45

CONFIDENTIAL TREATMENT REQUESTED
UNDER 17 C.F.R.(S)(S) 200.80(b) (4), 200.83 AND 240.24b-2

                                RELEASE AGREEMENT
                                -----------------

This Release Agreement ("Agreement"), dated and effective as of July 27, 2001
(the "Effective Date"), is by and between IntraBiotics Pharmaceuticals, Inc., a
Delaware corporation, ("IntraBiotics"), and Diversa Corporation, a Delaware
corporation ("Diversa," and, together with IntraBiotics, the "Parties"). Defined
terms used but not otherwise defined hereunder shall have the meanings given
them in that certain Drug Discovery, Development, and License Agreement, dated
as of January 6, 2001, between Diversa and IntraBiotics ("License Agreement").

                                    Recitals

         Whereas, Diversa and IntraBiotics entered into the License Agreement as
of January 6, 2001; and

         Whereas, Diversa and IntraBiotics entered into that certain binding
term sheet (the "Term Sheet") dated as of June 27, 2001 relating to the
termination of the License Agreement and the mutual release of the obligations
of both IntraBiotics and Diversa under such License Agreement; and

         Whereas, the Term Sheet contemplated that the Parties would
subsequently execute and deliver a definitive termination agreement, containing
the terms and conditions set forth in the Term Sheet and other terms and
conditions consistent the Term Sheet, that would supersede the Term Sheet; and

         Whereas, the Parties desire to set forth herein the terms governing
such definitive termination agreement.

         Now, Therefore, in consideration of the mutual covenants set forth in
this Agreement, the receipt and sufficiency of which the Parties hereby
acknowledge, the Parties hereby agree as follows:

     1.  Payments by IntraBiotics to Diversa. On [***], IntraBiotics paid
         -----------------------------------
Diversa the non-refundable, non-creditable sum of [***]. On [***], IntraBiotics
shall pay Diversa the non-refundable, non-creditable sum of [***] via wire
transfer in immediately available funds in accordance with the following
information:

                                      [***]

* CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

     2. Issuance of Warrants to Diversa. [***], IntraBiotics shall issue to
        -------------------------------
Diversa warrants to purchase 700,000 shares of common stock of IntraBiotics of
(collectively, the "Warrants") pursuant to the form of Warrant attached as
Exhibit A hereto. The shares of IntraBiotics's common stock into which the
Warrants are exercisable are subject to a Registration Rights Agreement between
IntraBiotics and Diversa in the form attached as Exhibit B hereto.

     3. Ownership of R&D Program Data & Materials. Diversa shall solely own all
        -----------------------------------------
of the data and materials generated by the research activities performed by
employees and consultants of Diversa pursuant to the R&D Program.

     4. Assignment of IntraBiotics's Assays to Diversa. Diversa shall solely own
        ----------------------------------------------
each and every primary, secondary, and tertiary assay used or discussed in the
Work Plan, which assays are described in Exhibit C hereto (the "Assays"). To
that end, IntraBiotics hereby assigns to Diversa such right, title in interest
in and to the Assays as IntraBiotics may have.

     5. Mutual Releases.
        ---------------

          a. Diversa Release. In consideration of the obligations, warranties
             ---------------
and representations of Diversa contained hereunder and contingent upon the
timely performance by IntraBiotics of its obligations hereunder, Diversa hereby
releases, acquits, and forever discharges IntraBiotics, its parents and
subsidiaries, and their officers, directors, agents, servants, employees,
attorneys, shareholders, partners, successors, assigns, affiliates, customers,
and clients of and from any and all claims liabilities, demands, causes of
action, costs, expenses, attorneys' fees, damages, indemnities and obligations
of every kind and nature, in law, equity, or otherwise, known and unknown,
suspected and unsuspected, disclosed and undisclosed, arising out of or in any
way related to agreements, acts or conduct at any time prior to the date of this
Term Sheet, including, but not limited to: all such claims and demands directly
or indirectly arising out of or in any way connected with the License Agreement;
and claims pursuant to any federal, state or local law or cause of action
including, but not limited to, tort law; contract law; fraud; defamation; and
breach of the implied covenant of good faith and fair dealing. In giving this
release, which includes claims which may be unknown to Diversa at present,
Diversa hereby acknowledges that it has read and understands Section 1542 of the
Civil Code of the State of California which reads as follows:

             "A general release does not extend to claims which the creditor
does not know or suspect to exist in his favor at the time of executing the
release, which if known by him must have materially affected his settlement with
the debtor."

             Diversa hereby expressly waives and relinquishes all rights and
benefits under Section 1542 of the Civil Code of the State of California and any
law

* CONFIDENTIAL TREATMENT REQUESTED

                                       2
<PAGE>

or legal principle of similar effect in any jurisdiction with respect to claims
released hereby.

          b. IntraBiotics Release. In consideration of the obligations,
             --------------------
warranties and representations of IntraBiotics contained hereunder, IntraBiotics
hereby releases, acquits, and forever discharges Diversa, its parents and
subsidiaries, and their officers, directors, agents, servants, employees,
attorneys, shareholders, partners, successors, assigns, affiliates, customers,
and clients of and from any and all claims liabilities, demands, causes of
action, costs, expenses, attorneys' fees, damages, indemnities and obligations
of every kind and nature, in law, equity, or otherwise, known and unknown,
suspected and unsuspected, disclosed and undisclosed, arising out of or in any
way related to agreements, acts or conduct at any time prior to the date of this
Term Sheet, including, but not limited to: all such claims and demands directly
or indirectly arising out of or in any way connected with the License Agreement;
and claims pursuant to any federal, state or local law or cause of action
including, but not limited to, tort law; contract law; fraud; defamation; and
breach of the implied covenant of good faith and fair dealing. In giving this
release, which includes claims which may be unknown to IntraBiotics at present,
IntraBiotics hereby acknowledges that it has read and understands Section 1542
of the Civil Code of the State of California which reads as follows:

             "A general release does not extend to claims which the creditor
does not know or suspect to exist in his favor at the time of executing the
release, which if known by him must have materially affected his settlement with
the debtor."

             IntraBiotics hereby expressly waives and relinquishes all rights
and benefits under Section 1542 of the Civil Code of the State of California and
any law or legal principle of similar effect in any jurisdiction with respect to
claims released hereby.

     6. Termination; Survival of Obligations. Except as set forth herein, the
        ------------------------------------
License Agreement is terminated. Only the confidentiality provisions of Sections
7.1, 7.2, and 7.3 of the License Agreement (and any applicable provisions of the
Confidential Disclosure Agreement between Diversa and IntraBiotics executed on
July 17, 2000 that do not contradict the terms of Sections 7.1, 7.2 or 7.3 of
the License Agreement) shall survive for a period of ten (10) years.

     7. No Admission of Liability. Diversa and IntraBiotics hereby acknowledge
        -------------------------
that this is a compromise settlement of various matters, and that the payments
in consideration of this Agreement shall not be construed to be an admission of
any liability or obligation by either party to the other party or to any other
person whomsoever.

     8. Publicity; Regulatory Filings. Diversa and IntraBiotics each acknowledge
        -----------------------------
and agree that neither the Term Sheet or this Agreement nor the terms contained
therein or herein shall be considered ether confidential or "Confidential
Information" as such term is defined in the License Agreement; provided,
                                                               --------
however, that information regarding the
-------

                                       3
<PAGE>

Assays shall be considered Confidential Information under the terms of the
License Agreement and, notwithstanding the exception in Section 7.3.3 of the
License Agreement, IntraBiotics shall have the obligations of a Receiving Party
with respect to information regarding the Assays and Diversa shall be considered
a Disclosing Party with respect to information regarding the Assays as such
terms are defined in the License Agreement. Accordingly, each of Diversa and
IntraBiotics shall be permitted to disclose the existence of the Term Sheet or
this Agreement and the terms thereof or hereof, except disclosures by
IntraBiotics with respect to the Assays, in such communications as such party
shall determine in its sole discretion, including, without limitation (i) in one
or more press releases and (ii) in one or more filings with the Securities and
Exchange Commission (or any other governmental agency, such as the Federal Trade
Commission, with which the License Agreement, Term Sheet, and/or Agreement is
required to be provided or filed by Diversa and/or IntraBiotics); provided,
however, that IntraBiotics shall not issue any press release regarding the Term
Sheet, this Agreement, or the termination of the License Agreement without the
express written consent of Diversa to the content of such press release.

     9. General Terms. This Agreement shall be governed by and construed in
        -------------
accordance with the laws of the State of California without regard to provisions
governing conflicts of law. This Agreement is not assignable in part or in whole
by any party without the prior written consent of the other party; provided,
however, that either party may assign this Agreement to its affiliates or to a
successor by merger or sale of all or substantially all of its business to which
this Agreement relates. The terms of this Agreement shall inure to the benefit
of and be binding upon the parties and their respective successors and assigns.
The terms and conditions of this Agreement constitute the entire agreement
between Diversa and IntraBiotics and supersede all previous negotiations or
agreements, either oral or written, between the parties with respect to the
subject matter of this Agreement, including, without limitation, the Term Sheet
and the License Agreement. This Agreement shall not be amended, supplemented or
abrogated other than by a written instrument signed by the authorized
representative of each Party. The failure of either Party to enforce at any time
any of the provisions of this Agreement, or any rights in respect of it, or to
exercise any election provided in it, shall in no way be considered to be a
waiver of such provisions, rights or elections, and shall in no way affect the
validity of this Agreement. If any action at law or in equity is necessary to
enforce or interpret the terms of this Agreement, the prevailing party shall be
entitled to reasonable attorneys' fees, costs and necessary disbursements in
addition to any other relief to which such party may be entitled. In the event
that any provision of this Agreement is, for any reason, held to be invalid or
unenforceable in any respect, such invalidity or unenforceability shall not
affect any other provision hereof, and the parties shall negotiate in good faith
to modify this Agreement to preserve (to the extent possible) their original
intent. Each party warrants that it has the authority to enter into this
Agreement on the basis of the terms and conditions herein and that it has not
made any other agreement inconsistent with its obligations under this Agreement.
This Agreement may be executed in one or more counterparts, each of which shall
be deemed to be an original and all of which taken together shall constitute one
and the same agreement.

                            (signature page follows)

                                       4
<PAGE>

In Witness Whereof, the undersigned have duly executed and delivered this
Agreement effective as of the date first above written.

                                    DIVERSA CORPORATION

                                    By: /s/ Karin Eastham
                                        -----------------------------------

                                    Name: Karin Eastham
                                          ---------------------------------

                                    Title: Senior Vice President, Finance
                                           --------------------------------
                                             and Chief Financial Officer
                                             ------------------------------

                                    INTRABIOTICS PHARMACEUTICALS, INC.

                                    By: /s/ Kenneth J. Kelley
                                        -----------------------------------

                                    Name: Kenneth J. Kelley
                                          ---------------------------------

                                    Title: President and CEO
                                           --------------------------------

                                       5
<PAGE>

                                    Exhibit A

                                                              Warrant No. CW - 4

THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE "ACT"), OR UNDER THE SECURITIES LAWS OF ANY STATE.
THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND
MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND
APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION
THEREFROM. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN
FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY
PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT AND ANY APPLICABLE
STATE SECURITIES LAWS.

                       WARRANT TO PURCHASE 700,000 SHARES
                               OF COMMON STOCK OF
                       INTRABIOTICS PHARMACEUTICALS, INC.
                          (Void after July 27, 2005)

         This certifies that Diversa Corporation, a Delaware corporation, or its
permitted assigns (the "Holder"), for value received, is entitled to purchase
from IntraBiotics Pharmaceuticals, Inc., a Delaware corporation (the "Company"),
having a place of business at 1245 Terra Bella Avenue, Mountain View, California
94043, a maximum of Seven Hundred Thousand (700,000) fully paid and
nonassessable shares of the Company's Common Stock ("Common Stock") of the same
class that currently is traded on the National Association of Securities Dealers
Automated Quotation System ("Nasdaq") National Market for cash at a price equal
to $2.00 per share (the "Stock Purchase Price") at any time or from time to time
up to and including 5:00 p.m. (Pacific time) on [***] (the "Expiration Date")
upon surrender to the Company at its principal office (or at such other location
as the Company may advise the Holder in writing) of this Warrant properly
endorsed with the Form of Subscription attached hereto duly filled in and signed
and upon payment in cash or wire transfer of the aggregate Stock Purchase Price
for the number of shares for which this Warrant is being exercised determined in
accordance with the provisions hereof. The Stock Purchase Price and the number
of shares purchasable hereunder are subject to adjustment as provided in Section
3 of this Warrant.

          This Warrant is subject to the following terms and conditions:

          1.   Exercise; Issuance of Certificates; Payment for Shares.

               1.1 General. This Warrant is exercisable at the option of the
          holder of record hereof, at any time or from time to time, up to the
          Expiration Date for all or any part of the shares of Common Stock (but
          not for a fraction of a share) which may be purchased hereunder. The
          Company agrees that the shares of Common Stock purchased under this
          Warrant shall be and are deemed to be issued to the Holder hereof as
          the record owner of

                                       1
<PAGE>

          such shares as of the close of business on the date on which this
          Warrant shall have been surrendered, properly endorsed, the completed,
          executed Form of Subscription delivered and payment made for such
          shares. Certificates for the shares of Common Stock so purchased,
          together with any other securities or property to which the Holder
          hereof is entitled upon such exercise, shall be delivered to the
          Holder hereof by the Company at the Company's expense within a
          reasonable time after the rights represented by this Warrant have been
          so exercised. In case of a purchase of less than all the shares which
          may be purchased under this Warrant, the Company shall cancel this
          Warrant and execute and deliver a new Warrant or Warrants of like
          tenor for the balance of the shares purchasable under the Warrant
          surrendered upon such purchase to the Holder hereof within a
          reasonable time. Each stock certificate so delivered shall be in such
          denominations of Common Stock as may be requested by the Holder hereof
          and shall be registered in the name of such Holder or in the name of
          Holder's affiliate and/or subsidiary as may be requested by the
          Holder.

               1.2  Net Issue Exercise. Notwithstanding any provisions herein to
          the contrary, if the fair market value of one share of the Company's
          Common Stock is greater than the Stock Purchase Price (at the date of
          calculation as set forth below), in lieu of exercising this Warrant
          for cash, the Holder may elect to receive shares equal to the value
          (as determined below) of this Warrant (or the portion thereof being
          canceled) by surrender of this Warrant at the principal office of the
          Company together with the properly endorsed Form of Subscription with
          notice of such election in which event the Company shall issue to the
          Holder a number of shares of Common Stock computed using the following
          formula:

                    X = Y (A-B)
                        -------
                          A

          Where X = the number of shares of Common Stock to be issued to the
          Holder

                                   Y = the number of shares of Common
                                   Stock purchasable under the Warrant
                                   or, if only a portion of the Warrant
                                   is being exercised, the portion of
                                   the Warrant being canceled (at the
                                   date of such calculation)

                                   A = the fair market value of one share of the
                                   Company's Common Stock (at the date of such
                                   calculation)

                                   B = Stock Purchase Price (as adjusted to the
                                   date of such calculation)

          For purposes of the above calculation, if the Common Stock is traded
on any established stock exchange or traded on the Nasdaq National Market or the
Nasdaq SmallCap Market, then the fair market value of one share of Common Stock
shall be the closing sales price for such stock (or the closing bid, if no sales
were reported) as quoted on such exchange or market (or the exchange or market
with the greatest volume of trading in the Common Stock) on the last market
trading day prior to the day of determination, as reported in The Wall Street
Journal or, if not

                                       2
<PAGE>

reported in The Wall Street Journal, then such other source as the Company's
Board of Directors reasonably deems reliable. In the absence of such markets for
Common Stock, the fair market value of one share of Common Stock shall be
determined by the Company's Board of Directors and the Holder in good faith.

     2.   Shares to be Fully Paid; Reservation of Shares. The Company covenants
and agrees that all shares of Common Stock which may be issued upon the exercise
of the rights represented by this Warrant will, upon issuance, be duly
authorized, validly issued, fully paid and nonassessable and free from all
preemptive rights of any stockholder and free of all taxes, liens and charges
with respect to the issue thereof. The Company further covenants and agrees
that, during the period within which the rights represented by this Warrant may
be exercised, the Company will at all times have authorized and reserved, for
the purpose of issue or transfer upon exercise of the subscription rights
evidenced by this Warrant, a sufficient number of shares of authorized but
unissued Common Stock, or other securities and property, when and as required to
provide for the exercise of the rights represented by this Warrant. The Company
will take all such action as may be necessary to assure that such shares of
Common Stock may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of any securities exchange
upon which the Common Stock may be listed; provided, however, that the Company
shall not be required to effect a registration under federal or state securities
laws solely because of such exercise. The Company will not take any action which
would result in any adjustment of the Stock Purchase Price (as set forth in
Section 3 hereof) if the total number of shares of Common Stock issuable after
such action upon exercise of all outstanding warrants, together with all shares
of Common Stock then outstanding and all shares of Common Stock then issuable
upon exercise of all options and upon the conversion of all convertible
securities then outstanding, would exceed the total number of shares of Common
Stock then authorized by the Company's Certificate of Incorporation.

     3.   Adjustment of Stock Purchase Price and Number of Shares. The Stock
Purchase Price and the number of shares purchasable upon the exercise of this
Warrant shall be subject to adjustment from time to time upon the occurrence of
certain events described in this Section 3. Upon each adjustment of the Stock
Purchase Price, the Holder of this Warrant shall thereafter be entitled to
purchase, at the Stock Purchase Price resulting from such adjustment, the number
of shares obtained by multiplying the Stock Purchase Price in effect immediately
prior to such adjustment by the number of shares purchasable pursuant hereto
immediately prior to such adjustment, and dividing the product thereof by the
Stock Purchase Price resulting from such adjustment.

          3.1  Subdivision or Combination of Stock. In case the Company shall at
any time subdivide its outstanding shares of Common Stock into a greater number
of shares, the Stock Purchase Price in effect immediately prior to such
subdivision shall be proportionately reduced, and conversely, in case the
outstanding shares of Common Stock of the Company shall be combined into a
smaller number of shares, the Stock Purchase Price in effect immediately prior
to such combination shall be proportionately increased.

          3.2  Dividends in Common Stock, Other Stock, Property,
Reclassification. If at any time or from time to time the holders of Common
Stock (or any shares of stock or other

                                      3
<PAGE>

securities at the time receivable upon the exercise of this Warrant) shall have
received or become entitled to receive, without payment therefor,

               a)   Common Stock or any shares of stock or other securities
     which are at any time directly or indirectly convertible into or
     exchangeable for Common Stock, or any rights or options to subscribe for,
     purchase or otherwise acquire any of the foregoing by way of dividend or
     other distribution,

               b)   any cash paid or payable otherwise than as a cash dividend,
     or

               c)   Common Stock or additional stock or other securities or
     property (including cash) by way of spinoff, split-up, reclassification,
     combination of shares or similar corporate rearrangement, (other than
     shares of Common Stock issued as a stock split or adjustments in respect of
     which shall be covered by the terms of Section 3.1 above),

               then and in each such case, the Holder hereof shall, upon the
exercise of this Warrant, be entitled to receive, in addition to the number of
shares of Common Stock receivable thereupon, and without payment of any
additional consideration therefor, the amount of stock and other securities and
property (including cash in the cases referred to in clauses (b) and (c) above)
which such Holder would hold on the date of such exercise had he been the holder
of record of such Common Stock as of the date on which holders of Common Stock
received or became entitled to receive such shares or all other additional stock
and other securities and property.

          3.3  Reorganization, Reclassification, Consolidation, Merger or Sale.
If any recapitalization, reclassification or reorganization of the capital stock
of the Company, or any consolidation or merger of the Company with another
corporation, or the sale of all or substantially all of its assets or other
transaction shall be effected in such a way that holders of Common Stock shall
be entitled to receive stock, securities, or other assets or property (an
"Organic Change"), then, as a condition of such Organic Change, lawful and
adequate provisions shall be made by the Company whereby the Holder hereof shall
thereafter have the right to purchase and receive (in lieu of the shares of the
Common Stock of the Company immediately theretofore purchasable and receivable
upon the exercise of the rights represented hereby) such shares of stock,
securities or other assets or property as may be issued or payable with respect
to or in exchange for a number of outstanding shares of such Common Stock equal
to the number of shares of such stock immediately theretofore purchasable and
receivable upon the exercise of the rights represented hereby. In the event of
any Organic Change, appropriate provision shall be made by the Company with
respect to the rights and interests of the Holder of this Warrant to the end
that the provisions hereof (including, without limitation, provisions for
adjustments of the Stock Purchase Price and of the number of shares purchasable
and receivable upon the exercise of this Warrant) shall thereafter be
applicable, in relation to any shares of stock, securities or assets thereafter
deliverable upon the exercise hereof. The Company will not effect any such
consolidation, merger or sale unless, prior to the consummation thereof, the
successor corporation (if other than the Company) resulting from such
consolidation or the corporation purchasing such assets shall assume by written
instrument the obligation to deliver to such Holder such shares of stock,
securities or assets as, in accordance with the foregoing provisions, such
Holder may be entitled to purchase.

                                      4
<PAGE>

          3.4  Certain Events. If any change in the outstanding Common Stock of
the Company or any other event occurs as to which the other provisions of this
Section 3 are not strictly applicable or if strictly applicable would not fairly
protect the purchase rights of the Holder of the Warrant in accordance with such
provisions, then the Board of Directors of the Company shall make an adjustment
in the number and class of shares available under the Warrant, the Stock
Purchase Price or the application of such provisions, so as to protect such
purchase rights as aforesaid. The adjustment shall be such as will give the
Holder of the Warrant upon exercise for the same aggregate Stock Purchase Price
the total number, class and kind of shares as such Holder would have owned had
the Warrant been exercised prior to the event and had such Holder continued to
hold such shares until after the event requiring adjustment.

          3.5  Notices of Change.

               a)   Immediately upon any adjustment in the number or class of
shares subject to this Warrant and of the Stock Purchase Price, the Company
shall give written notice thereof to the Holder, setting forth in reasonable
detail and certifying the calculation of such adjustment.

               b)   The Company shall give written notice to the Holder at least
15 calendar days prior to the date on which the Company closes its books or
takes a record for determining rights to receive any dividends or distributions
or any right to subscribe for, purchase or otherwise acquire any shares of stock
of any class or any other securities or property, or to receive any other right.

               c)   The Company shall give written notice to the Holder at least
20 calendar days prior to the date on which an Organic Change shall take place,
including in such notice the date as of which the Organic Change is expected to
become effective and the date as of which it is expected that holders of Common
Stock of record shall be entitled to exchange their shares of Common Stock for
securities or other property, if any, deliverable upon such Organic Change.

               d)   The Company shall initiate the delivery of written notice to
the Holder of any voluntary or involuntary dissolution, liquidation or winding-
up of the Company (the "Dissolution") on the date such Dissolution is publicly
announced, including in such notice the date as of which the Dissolution is
expected to become effective and the date as of which it is expected that
holders of Common Stock of record shall be entitled to exchange their shares of
Common Stock for securities or other property, if any.

     4.   Listing. The Company shall file any forms and do any acts as shall be
required from time to time to secure the listing or quotation of the Common
Stock issuable upon exercise of the Warrant with each national securities
exchange or automated quotation system, if any, upon which shares of such
securities are then listed or traded and shall maintain, so long as any other
shares of such securities shall be so listed or traded, such listing or
quotation of all securities issued or issuable upon the exercise of this
Warrant.

     5.   Issue Tax. The issuance of certificates for shares of Common Stock
upon the exercise of the Warrant shall be made without charge to the Holder of
the Warrant for any issue

                                      5
<PAGE>

tax (other than any applicable income taxes) in respect thereof; provided,
however, that the Company shall not be required to pay any tax which may be
payable in respect of any transfer involved in the issuance and delivery of any
certificate in a name other than that of the then Holder of the Warrant being
exercised.

     6.   Closing of Books. The Company will at no time close its transfer books
against the transfer of any warrant or of any shares of Common Stock issued or
issuable upon the exercise of any warrant in any manner which interferes with
the timely exercise of this Warrant.

     7.   No Voting or Dividend Rights; Limitation of Liability. Nothing
contained in this Warrant shall be construed as conferring upon the Holder
hereof the right to vote or to consent or to receive notice as a stockholder of
the Company or any other matters or any rights whatsoever as a stockholder of
the Company. No dividends or interest shall be payable or accrued in respect of
this Warrant or the interest represented hereby or the shares purchasable
hereunder until, and only to the extent that, this Warrant shall have been
exercised. No provisions hereof, in the absence of affirmative action by the
holder to purchase shares of Common Stock, and no mere enumeration herein of the
rights or privileges of the holder hereof, shall give rise to any liability of
such Holder for the Stock Purchase Price or as a stockholder of the Company,
whether such liability is asserted by the Company or by its creditors.

     8.   Representations of Holder. Holder represents that by reason of its
own, or of its management's, knowledge and experience in financial and business
matters, Holder is capable of evaluating the merits and risks of its investment
in the Company and has the capacity to protect its own interests in connection
with the issuance of this Warrant and the shares of Common Stock issuable upon
the exercise thereof. Holder represents that it is acquiring such securities for
its own account for investment only, and not with a view towards their
distribution.

     9.   Warrants Transferable. This Warrant is not transferable except to an
affiliate or a subsidiary of Holder; provided that Holder provides prior written
notice of such transfer to the Company, such transferee agrees to be bound by
the obligations hereunder, and the Company may treat such transferee as the
absolute owner hereof for any purpose and as the person entitled to exercise the
rights represented by this Warrant.

     10.  Rights and Obligations Survive Exercise of Warrant. The rights and
obligations of the Company, of the holder of this Warrant and of the holder of
shares of Common Stock issued upon exercise of this Warrant, shall survive the
exercise of this Warrant.

     11.  Modification and Waiver. This Warrant and any provision hereof may be
changed, waived, discharged or terminated only by an instrument in writing
signed by the party against which enforcement of the same is sought.

     12.  Notices. Any notice, request or other document required or permitted
to be given or delivered to the holder hereof or the Company shall be in
writing, shall refer specifically to this Warrant and shall be personally
delivered or shall be sent by certified mail or internationally recognized
overnight courier, postage prepaid, to Holder at its address as shown on the
signature page hereto or to the Company at the address indicated therefor in the
first paragraph of this Warrant or such other address as either may from time to
time provide to the

                                      6
<PAGE>

other in writing. Any delivery, notice, request or other document given in
conformity with this Section 12 shall be deemed to be effective when received by
the addressee.

     13.  Binding Effect on Successors. This Warrant shall be binding upon any
corporation succeeding the Company by merger, consolidation or acquisition of
all or substantially all of the Company's assets. All of the obligations of the
Company relating to the Common Stock issuable upon the exercise of this Warrant
shall survive the exercise and termination of this Warrant. All of the covenants
and agreements of the Company shall inure to the benefit of the successors and
assigns of the Holder hereof.

     14.  Descriptive Headings and Governing Law. The description headings of
the several sections and paragraphs of this Warrant are inserted for convenience
only and do not constitute a part of this Warrant. This Warrant shall be
construed and enforced in accordance with, and the rights of the parties shall
be governed by, the laws of the State of California.

     15.  Lost Warrants. The Company represents and warrants to the Holder
hereof that upon receipt of evidence reasonably satisfactory to the Company of
the loss, theft, destruction, or mutilation of this Warrant and, in the case of
any such loss, theft or destruction, upon receipt of an indemnity reasonably
satisfactory to the Company, or in the case of any such mutilation upon
surrender and cancellation of such Warrant, the Company, at its expense, will
make and deliver a new Warrant, of like tenor, in lieu of the lost, stolen,
destroyed or mutilated Warrant.

     16.  Fractional Shares. No fractional shares shall be issued upon exercise
of this Warrant. The Company shall, in lieu of issuing any fractional share, pay
the holder entitled to such fraction a sum in cash equal to such fraction
multiplied by the then effective Stock Purchase Price.

                     [THIS SPACE INTENTIONALLY LEFT BLANK]

                                      7
<PAGE>

In Witness Whereof, the Company has caused this Warrant to be duly executed by
its officers, thereunto duly authorized this 27th day of July, 2001.

                                            Intrabiotics Pharmaceuticals, Inc.

                                            By:  /s/ Kenneth J. Kelley
                                              --------------------------------
                                              Kenneth Kelley, President and CEO

HOLDER:

Diversa Corporation

 By: /s/ Karin Eastham
     ----------------------------------
     Karin Eastham
     Senior Vice President, Finance and
     Chief Financial Officer

 Address:  4955 Directors Place
           San Diego, CA 92121

                                       8
<PAGE>

                                SUBSCRIPTION FORM

                                             Date:  __________, 200_

IntraBiotics Pharmaceuticals, Inc.
1245 Terra Bella Avenue
Mountain View, CA 94043
Attn: President

Ladies and Gentlemen:

[_]      The undersigned hereby elects to exercise the warrant issued to it by
         IntraBiotics Pharmaceuticals, Inc. (the "Company") and dated July 27,
         2001 Warrant No. CW-4 (the "Warrant") and to purchase thereunder
         __________________________________ shares of the Common Stock of the
         Company (the "Shares") at a purchase price of $2.00 per Share or an
         aggregate purchase price of ________________ Dollars ($__________) (the
         "Purchase Price").

[_]      The undersigned hereby elects to convert ______________________ percent
         (___%) of the value of the Warrant pursuant to the provisions of
         Section 1.2 of the Warrant.

Pursuant to the terms of the Warrant the undersigned has delivered the Purchase
Price herewith in full in cash or wire transfer.

                                           Very truly yours,

                                           _____________________________________
                                              Print Entity Name, if applicable

                                           By:__________________________________

                                           Print Name:__________________________

                                           Title:_______________________________

                                       9
<PAGE>

                                   Exhibit B

                         Registration Rights Agreement

     This Registration Rights Agreement (the "Agreement") is entered into as of
the 27th day of July, 2001, by and between Intrabiotics Pharmaceuticals, Inc., a
Delaware corporation (the "Company"), and Diversa Corporation, a Delaware
corporation (the "Holder").

Recitals

     Whereas, pursuant to that certain Release Agreement by and between the
Company and Holder, dated as of July 27, 2001 (the "Release Agreement"), the
Company has issued a warrant (the "Warrant"), to purchase up to 700,000 shares
of common stock of the Company (the "Warrant Shares") to Holder; and

     Whereas, in connection with the Release Agreement and issuance of the
Warrant, the Company has agreed to extend to Holder certain registration rights
for such Warrant Shares.

Agreement

     Now Therefore, in consideration of the mutual agreements, covenants and
conditions set forth herein, the parties to this Agreement agree as follows:

1.   Definitions. The following terms shall have the following meanings for
purposes of this Agreement:

          1.1  "Act" shall mean the Securities Act of 1933, as amended.

          1.2  "Exchange Act" shall mean the Securities Exchange Act of 1934, as
amended.

          1.3  "Holder" shall mean the holder of Registrable Securities.

          1.4  "Investors Rights Agreement" shall mean that certain Amended and
Restated Investors Rights Agreement by and between the Company and the investors
named therein, dated as of October 15, 1999, as the same may from time to time
be amended, modified, supplemented or restated.

          1.5  "Register," "registered" and "registration" refer to a
registration effected by preparing and filing a registration statement or
similar document in compliance with the Act, and the declaration or ordering of
effectiveness of such registration statement or document.

          1.6  "Registrable Securities" shall mean the Warrant Shares issuable
or issued to the Holder upon exercise of the Warrant.

                                       1
<PAGE>

     1.7  "Rule 144" shall mean Rule 144 under the Act, as such Rule may be
amended from time to time, or any similar rule or regulation hereafter adopted
by the SEC (excluding Rule 144A).

     1.8  "SEC" shall mean the Securities and Exchange Commission.

2.   Registration Rights.

     2.1  Company Registration. If (but without any obligation to do so) the
Company proposes to register (including for this purpose a registration effected
by the Company for stockholders other than the Holder) any of its stock or other
securities under the Act in connection with the public offering of such
securities solely for cash (other than a registration relating solely to the
sale of securities to participants in a Company stock plan, a registration on
any form which does not include substantially the same information as would be
required to be included in a registration statement covering the sale of the
Registrable Securities or a registration in which the only common stock being
registered is common stock issuable upon conversion of debt securities which are
also being registered), the Company shall, at such time, promptly give Holder
written notice of such registration. Upon the written request of Holder given
within twenty (20) days after mailing of such notice by the Company in
accordance with Section 3.6, the Company shall, subject to the provisions of
Section 2.5, cause to be registered under the Act all of the Registrable
Securities that Holder has requested to be registered.

     2.2  Obligations of the Company. Whenever required under this Agreement to
effect the registration of any Registrable Securities, the Company shall, as
expeditiously as reasonably possible:

          (a)  Prepare and file with the SEC a registration statement with
respect to such Registrable Securities and use its best efforts to cause such
registration statement to become effective, and, upon the request of the Holder,
keep such registration statement effective for a period of up to one hundred
twenty (120) days or until the distribution contemplated in the registration
statement has been completed; provided, however, that (i) such 120-day period
shall be extended for a period of time equal to the period the Holder refrains
from selling any securities included in such registration at the request of an
underwriter of common stock (or other securities) of the Company; and (ii) in
the case of any registration of Registrable Securities on Form S-3 which are
intended to be offered on a continuous or delayed basis, such 120-day period
shall be extended, if necessary, to keep the registration statement effective
until all such Registrable Securities are sold, provided that Rule 415, or any
successor rule under the Act, permits an offering on a continuous or delayed
basis, and provided further that applicable rules under the Act governing the
obligation to file a post-effective amendment permit, in lieu of filing a post-
effective amendment which (I) includes any prospectus required by Section
10(a)(3) of the Act or (II) reflects facts or events representing a material of
fundamental change in the information set forth in the registration statement,
the incorporation by reference of information required to be included in (I) and
(II) above to be contained in periodic reports filed pursuant to Section 13 or
15(d) of the Exchange Act in the registration statement.

          (b)  Prepare and file with the SEC such amendments and supplements to
such registration statement and the prospectus used in connection with such
registration statement as

                                       2
<PAGE>

may be necessary to comply with the provisions of the Act with respect to the
disposition of all securities covered by such registration statement.

          (c)  Furnish to the Holder such numbers of copies of a prospectus,
including a preliminary prospectus, in conformity with the requirements of the
Act, and such other documents as Holder may reasonably request in order to
facilitate the disposition of Registrable Securities owned by it.

          (d)  Use its best efforts to register and qualify the securities
covered by such registration statement under such other securities or blue sky
laws of such jurisdictions as shall be reasonably requested by the Holder;
provided that the Company shall not be required in connection therewith or as a
condition thereto to qualify to do business or to file a general consent to
service of process in any such states or jurisdictions, unless the Company is
already subject to service in such jurisdiction and except as may be required by
the Act.

          (e)  In the event of any underwritten public offering, enter into and
perform its obligations under an underwriting agreement, in usual and customary
form, with the managing underwriter of such offering. If Holder participates in
such underwriting, it shall also enter into and perform its obligations under
such an agreement.

          (f)  Notify Holder at any time when a prospectus relating to the
registration statement is required to be delivered under the Act of the
happening of any event as a result of which the prospectus included in such
registration statement, as then in effect, includes an untrue statement of a
material fact or omits to state a material fact required to be stated therein or
necessary to make the statements therein not misleading in the light of the
circumstances then existing.

          (g)  Cause all such Registrable Securities registered pursuant hereto
to be listed on each securities exchange on which similar securities issued by
the Company are then listed.

          (h)  Provide a transfer agent and registrar for all Registrable
Securities registered pursuant hereto and a CUSIP number for all such
Registrable Securities, in each case not later than the effective date of such
registration.

          (i)  Furnish, at the request of Holder requesting registration of
Registrable Securities pursuant to this Section 2, on the date that such
Registrable Securities are delivered to the underwriters for sale in connection
with a registration pursuant to this Section 2, if such securities are being
sold through underwriters, or, if such securities are not being sold through
underwriters, on the date that the registration statement with respect to such
securities becomes effective, (i) an opinion, dated such date, of the counsel
representing the Company for the purposes of such registration, in form and
substance as is customarily given to underwriters in an underwritten public
offering, addressed to the underwriters, if any, and to the Holder and (ii) a
letter dated such date, from the independent certified public accountants of the
Company, in form and substance as is customarily given by independent certified
public accountants to underwriters in an underwritten public offering, addressed
to the underwriters, if any, and to the Holder.

                                       3
<PAGE>

     2.3  Furnish Information. It shall be a condition precedent to the
obligations of the Company to take any action pursuant to this Section 2 with
respect to the Registrable Securities that Holder shall furnish to the Company
such information regarding itself, the Registrable Securities held by it, and
the intended method of disposition of such securities as shall be required to
effect the registration of Holder's Registrable Securities.

     2.4  Expenses of Company Registration. The Company shall bear and pay all
expenses incurred in connection with any registration, filing or qualification
of the Registrable Securities with respect to the registration pursuant to
Section 2.1 for Holder (which right may be assigned as provided in Section
2.10), including (without limitation) all registration, filing and qualification
fees, printers and accounting fees relating or apportionable thereto and the
fees and disbursements of one counsel for the selling stockholders included in
such registration selected by them, but excluding underwriting discounts and
commissions relating to the Registrable Securities.

     2.5  Underwriting Requirements. In connection with any offering involving
an underwriting of shares of the Company's capital stock, the Company shall not
be required under Section 2.1 to include any of the Holder's securities in such
underwriting unless Holder accepts the terms of the underwriting as agreed upon
between the Company and the underwriters selected by it (or by other persons
entitled to select the underwriters), and then only in such quantity as the
underwriters determine in their sole discretion will not jeopardize the success
of the offering by the Company. If the total amount of securities, including
Registrable Securities, requested by stockholders to be included in such
offering exceeds the amount of securities sold other than by the Company that
the underwriters determine in their sole discretion is compatible with the
success of the offering, then the Company shall be required to include in the
offering only that number of such securities, including Registrable Securities,
which the underwriters determine in their sole discretion will not jeopardize
the success of the offering (the securities so included to be apportioned pro
rata among the selling stockholders according to the total amount of securities
entitled to be included therein owned by each selling stockholder or in such
other proportions as shall mutually be agreed to by such selling stockholders)
but in no event shall (i) the amount of securities of all selling stockholders
included in the offering be reduced below twenty percent (20%) of the total
amount of securities included in such offering, or (ii) notwithstanding (i)
above, any shares being sold by a stockholder exercising a demand registration
right similar to that granted in Section 1.2 of the Investors Rights Agreement
be excluded from such offering. For purposes of the preceding subsections
concerning apportionment, for any selling stockholder which is a holder of
registrable securities under this Agreement or the Investors Rights Agreement
and which is a partnership or corporation, the partners, retired partners and
stockholders of such holder, or the estates and family members of any such
partners and retired partners and any trusts for the benefit of any of the
foregoing persons shall be deemed to be a single "selling stockholder," and any
pro-rata reduction with respect to such "selling stockholder," shall be based
upon the aggregate amount of shares carrying registration rights owned by all
entities and individuals included in such "selling stockholder," as defined in
this sentence.

     2.6  Delay of Registration. Holder shall not have any right to obtain or
seek an injunction restraining or otherwise delaying any such registration as
the result of any controversy that might arise with respect to the
interpretation or implementation of this Section 2.

                                       4
<PAGE>

     2.7  Indemnification. In the event any Registrable Securities are included
in a registration statement under this Section 2:

          (a)  To the extent permitted by law, the Company will indemnify and
hold harmless Holder, any underwriter (as defined in the Act) for Holder and
each person, if any, who controls such Holder or underwriter within the meaning
of the Act or the Exchange Act, against any losses, claims, damages or
liabilities (joint or several) to which they may become subject under the Act,
the Exchange Act or other federal or state law, insofar as such losses, claims,
damages or liabilities (or actions in respect thereof) arise out of or are based
upon any of the following statements, omissions or violations (each, a
"Violation"): (i) any untrue statement or alleged untrue statement of a material
fact contained in such registration statement, including any preliminary
prospectus or final prospectus contained therein or any amendments or
supplements thereto, (ii) the omission or alleged omission to state therein a
material fact required to be stated therein, or necessary to make the statements
therein not misleading, or (iii) any violation or alleged violation by the
Company of the Act, the Exchange Act, any state securities law or any rule or
regulation promulgated under the Act, or the Exchange Act or any state
securities law; and the Company will pay to such Holder, underwriter or
controlling person, as incurred, any legal or other expenses reasonably incurred
by them in connection with investigating or defending any such loss, claim,
damage, liability or action; provided, however, that the indemnity agreement
contained in this subsection 2.7(a) shall not apply to amounts paid in
settlement of any such loss, claim, damage, liability or action if such
settlement is effected without the consent of the Company (which consent shall
not be unreasonably withheld), nor shall the Company be liable in any such case
for any such loss, claim, damage, liability or action to the extent that it
arises out of or is based upon a Violation which occurs in reliance upon and in
conformity with written information furnished expressly for use in connection
with such registration by any such Holder, underwriter or controlling person.

          (b)  To the extent permitted by law, Holder will indemnify and hold
harmless the Company, each of its directors, each of its officers who has signed
the registration statement, each person, if any, who controls the Company within
the meaning of the Act, any underwriter, any other holder selling securities in
such registration statement and any controlling person of any such underwriter
or other holder, against any losses, claims, damages or liabilities (joint or
several) to which any of the foregoing persons may become subject, under the
Act, or the Exchange Act or other federal or state law, insofar as such losses,
claims, damages or liabilities (or actions in respect thereto) arise out of or
are based upon any Violation, in each case to the extent (and only to the
extent) that such Violation occurs in reliance upon and in conformity with
written information furnished by Holder expressly for use in connection with
such registration; and such Holder will pay, as incurred, any legal or other
expenses reasonably incurred by any person intended to be indemnified pursuant
to this subsection 2.7(b), in connection with investigating or defending any
such loss, claim, damage, liability or action; provided, however, that the
indemnity agreement contained in this subsection 2.7(b) shall not apply to
amounts paid in settlement of any such loss, claim, damage, liability or action
if such settlement is effected without the consent of the Holder, which consent
shall not be unreasonably withheld; provided, that, in no event shall any
indemnity under this subsection 2.7(b) exceed the gross proceeds from the
offering received by the Holder.

                                       5
<PAGE>

          (c)  Promptly after receipt by an indemnified party under this Section
2.7 of notice of the commencement of any action (including any governmental
action), such indemnified party will, if a claim in respect thereof is to be
made against any indemnifying party under this Section 2.7, deliver to the
indemnifying party a written notice of the commencement thereof and the
indemnifying party shall have the right to participate in, and, to the extent
the indemnifying party so desires, jointly with any other indemnifying party
similarly noticed, to assume the defense thereof with counsel mutually
satisfactory to the parties; provided, however, that an indemnified party
(together with all other indemnified parties which may be represented without
conflict by one counsel) shall have the right to retain one separate counsel,
with the fees and expenses to be paid by the indemnifying party, if
representation of such indemnified party by the counsel retained by the
indemnifying party would be inappropriate due to actual or potential differing
interests between such indemnified party and any other party represented by such
counsel in such proceeding. The failure to deliver written notice to the
indemnifying party within a reasonable time of the commencement of any such
action, if prejudicial to its ability to defend such action, shall relieve such
indemnifying party of any liability to the indemnified party under this Section
2.7, but the omission so to deliver written notice to the indemnifying party
will not relieve it of any liability that it may have to any indemnified party
otherwise than under this Section 2.7.

          (d)  If the indemnification provided for in this Section 2.7 is held
by a court of competent jurisdiction to be unavailable to an indemnified party
with respect to any loss, liability, claim, damage or expense referred to
therein, then the indemnifying party, in lieu of indemnifying such indemnified
party hereunder, shall contribute to the amount paid or payable by such
indemnified party as a result of such loss, liability, claim, damage or expense
in such proportion as is appropriate to reflect the relative fault of the
indemnifying party on the one hand and of the indemnified party on the other in
connection with the statements or omissions that resulted in such loss,
liability, claim, damage or expense as well as any other relevant equitable
considerations. The relative fault of the indemnifying party and of the
indemnified party shall be determined by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or the
omission to state a material fact relates to information supplied by the
indemnifying party or by the indemnified party and the parties' relative intent,
knowledge, access to information, and opportunity to correct or prevent such
statement or omission.

          (e)  Notwithstanding the foregoing, to the extent that the provisions
on indemnification and contribution contained in the underwriting agreement
entered into in connection with the underwritten public offering are in conflict
with the foregoing provisions, the provisions in the underwriting agreement
shall control.

          (f)  The obligations of the Company and Holder under this Section 2.7
shall survive the completion of any offering of Registrable Securities in a
registration statement under this Section 2 and otherwise.

     2.8  Reports under Securities Exchange Act of 1934. With a view to making
available to the Holder the benefits of Rule 144 promulgated under the Act and
any other rule or regulation of the SEC that may at any time permit Holder to
sell securities of the Company to the public without registration or pursuant to
a registration on Form S-3, the Company agrees to:

                                       6
<PAGE>

          (a)  make and keep public information available, as those terms are
understood and defined in SEC Rule 144;

          (b)  take such action, including the voluntary registration of its
common stock under Section 12 of the Exchange Act, as is necessary to enable the
Holder to utilize Form S-3 for the sale of its Registrable Securities, such
action to be taken as soon as practicable after the end of the fiscal year in
which the first registration statement filed by the Company for the offering of
its securities to the general public is declared effective;

          (c)  file with the SEC in a timely manner all reports and other
documents required of the Company under the Act and the Exchange Act; and

          (d)  furnish to Holder, so long as the Holder owns any Registrable
Securities, forthwith upon request (i) a written statement by the Company that
it has complied with the reporting requirements of SEC Rule 144, the Act and the
Exchange Act, or that it qualifies as a registrant whose securities may be
resold pursuant to Form S-3 (at any time after it so qualifies), (ii) a copy of
the most recent annual or quarterly report of the Company and such other reports
and documents so filed by the Company, and (iii) such other information as may
be reasonably requested in availing Holder of any rule or regulation of the SEC
which permits the selling of any such securities without registration or
pursuant to such form.

     2.9  Form S-3 Registration. In case the Company shall receive from Holder a
written request that the Company effect a registration on Form S-3 and any
related qualification or compliance with respect to all or a part of the
Registrable Securities owned by Holder, the Company will:

          (a)  as soon as practicable, effect such registration and all such
qualifications and compliances as may be so requested and as would permit or
facilitate the sale and distribution of all or such portion of Holder's
Registrable Securities as are specified in such request; provided, however, that
the Company shall not be obligated to effect any such registration,
qualification or compliance, pursuant to this Section 2.9: (1) if Form S-3 is
not available for such offering by Holder; (2) if Holder, together with the
holders of any other securities of the Company entitled to inclusion in such
registration, proposes to sell Registrable Securities and such other securities
(if any) at an aggregate price to the public (net of any underwriters' discounts
or commissions) of less than $1,000,000; (3) if the Company shall furnish to
Holder a certificate signed by the President of the Company stating that, in the
good faith judgment of the Board of Directors of the Company, it would be
seriously detrimental to the Company and its stockholders for such Form S-3
registration to be effected at such time, in which event the Company shall have
the right to defer the filing of the Form S-3 registration statement for a
period of not more than sixty (60) days after receipt of the request of Holder
under this Section 2.9; provided, however, that the Company shall not utilize
this right more than once in any twelve-month period; (4) if the Company has
already effected three registrations on Form S-3 for the Holder pursuant to this
Section 2 or holders of registrable securities pursuant to Section 1.12 of the
Investors Rights Agreement; or (5) in any particular jurisdiction in which the
Company would be required to qualify to do business or to execute a general
consent to service of process in effecting such registration, qualification or
compliance.

                                       7
<PAGE>

          (b)  Subject to the foregoing, the Company shall file a registration
statement covering the Registrable Securities as soon as practicable after
receipt of the request of Holder. All expenses incurred in connection with a
registration requested pursuant to this Section 2.9, including (without
limitation) all registration, filing, qualification, printer's and accounting
fees and the reasonable fees and disbursements of one counsel for the selling
stockholders participating in such registration and counsel for the Company, but
excluding any underwriters' discounts or commissions associated with Registrable
Securities, shall be borne by the Company. Registrations effected pursuant to
this Section 2.9 shall not be counted as registrations effected pursuant to
Section 2.1.

          (c)  Following the effectiveness of a registration statement filed
pursuant to this section 2.9, the Company may, at any time, suspend the
effectiveness of such registration statement for up to 60 days, as appropriate
(a "Suspension Period"), by giving notice to Holder, if the Company shall have
determined that the Company may be required to disclose any material corporate
development which disclosure may have a material adverse effect on the Company.
Notwithstanding the foregoing, no more than one Suspension Period may occur in
any 12-month period. The period of any such suspension of the registration
statement shall be added to the period of time the Company agrees to keep the
registration statement effective as provided in Section 2.2. Company shall use
its reasonable efforts to limit the duration and number of any Suspension
Periods. Holder agrees that, upon receipt of any notice from the Company of a
Suspension Period, such Holder shall forthwith discontinue disposition of shares
covered by such registration statement or prospectus until such Holder (i) is
advised in writing by the Company that the use of the applicable prospectus may
be resumed, (ii) has received copies of a supplemental or amended prospectus, if
applicable, and (iii) has received copies of any additional or supplemental
filings which are incorporated or deemed to be incorporated by reference in such
prospectus.

     2.10 Assignment of Registration Rights. The rights to cause the Company to
register Registrable Securities pursuant to this Agreement may be assigned (but
only with all related obligations) by Holder to a transferee or assignee of all
of the Registrable Securities (subject to appropriate adjustment for stock
splits, stock dividends, combinations and other recapitalizations); provided
that (a) the Company is, within a reasonable time after such transfer, furnished
with written notice of the name and address of such transferee or assignee and
the securities with respect to which such registration rights are being
assigned; (b) such transferee or assignee agrees in writing to be bound by and
subject to the terms and conditions of this Agreement; and (c) such assignment
shall be effective only if immediately following such transfer the further
disposition of such securities by the transferee or assignee is restricted under
the Act. For the purposes of determining the number of shares of Registrable
Securities held by a transferee or assignee, the holdings of transferees and
assignees of Holder which are wholly-owned subsidiaries or affiliates of Holder
shall be aggregated together and with Holder; provided that all assignees and
transferees who would not qualify individually for assignment of registration
rights shall have a single attorney-in-fact for the purpose of exercising any
rights, receiving notices or taking any action under this Agreement.

                                       8
<PAGE>

     2.11 Termination or Suspension of Registration Rights.

          (a)  Holder shall not be entitled to exercise any right provided for
in this Agreement after July 27, 2005.

          (b)  In addition, the right of Holder to request registration or
inclusion in any registration pursuant to this Agreement shall be suspended
during any period of time when all shares of Registrable Securities held or
entitled to be held upon conversion by Holder may immediately be sold under Rule
144 during any 90-day period; provided, however, that the provisions of this
Section 2.11(b) shall not apply to Holder if Holder owns more than one percent
(1%) of the Company's outstanding stock until such time as Holder owns less than
one percent (1%) of the outstanding stock of the Company.

3.   Miscellaneous.

     3.1  Governing Law. The Agreement shall be governed by and construed under
the laws of the State of California as applied to agreements among California
residents entered into and to be performed entirely within California.

     3.2  Successors and Assigns. Except as otherwise expressly provided herein,
the provisions hereof shall inure to the benefit of, and be binding upon, the
successors, assigns, heirs, executors, and administrators of the parties hereto
and shall inure to the benefit of and be enforceable by each person who shall be
a holder of Registrable Securities from time to time; provided however, that
prior to the receipt by the Company of adequate written notice of the transfer
of any Registrable Securities specifying the full name and address of the
transferee, the Company may deem and treat the person listed as the holder of
such shares in its records as the absolute owner and holder of such shares for
all purposes.

     3.3  Entire Agreement. This Agreement constitutes the full and entire
understanding and agreement between the parties with regard to the subjects
hereof and supersedes any prior agreements by the Company for the benefit of any
party hereto regarding the registration of securities. No party shall be liable
or bound to any other in any manner by any representations, warranties,
covenants and agreements except as specifically set forth herein.

     3.4  Severability. In case any provision of the Agreement shall be invalid,
illegal, or unenforceable, the validity, legality, and enforceability of the
remaining provisions shall not in any way be affected or impaired thereby.

     3.5  Amendments and Waivers. Any term of this Agreement may be amended and
the observance of any term of this Agreement may be waived (either generally or
in a particular instance and either retroactively or prospectively), only with
the written consent of the Company and the holders of a majority of the
Registrable Securities. Any amendment or waiver effected in accordance with this
paragraph shall be binding upon Holder, any future holder of Registrable
Securities and the Company.

                                       9
<PAGE>

     3.6  Notices. All notices required or permitted hereunder shall be in
writing and shall be deemed effectively given: (a) upon personal delivery to the
party to be notified, (b) when sent by confirmed facsimile if sent during normal
business hours of the recipient; if not, then on the next business day, (c) five
(5) days after having been sent by registered or certified mail, return receipt
requested, postage prepaid, or (d) one (1) day after deposit with a nationally
recognized overnight courier, specifying next day delivery, with written
verification of receipt. All communications shall be sent to the party to be
notified at the address or facsimile number set forth below or at such other
address as such party may designate by ten (10) days advance written notice to
the other parties hereto:

          if to the Company:
                              IntraBiotics Pharmaceuticals, Inc.
                              1245 Terra Bella Avenue
                              Mountain View, CA 94043
                              Attention: Kenneth Kelley, President
                              Telephone: (650) 526-6800
                              Facsimile: (650) 969-0663

          if to the Holder:
                              Diversa Corporation
                              4955 Directors Place
                              San Diego, CA  92121
                              Attention: Karin Eastham, Senior Vice
                                President, Finance and Chief Financial
                                Officer
                              Telephone: (858) 526-5000
                              Facsimile: (858) 526-5050

     3.7  Attorneys' Fees. In the event that any dispute among the parties to
this Agreement should result in litigation, the prevailing party in such dispute
shall be entitled to recover from the losing party all fees, costs and expenses
of enforcing any right of such prevailing party under or with respect to this
Agreement, including without limitation, such reasonable fees and expenses of
attorneys and accountants, which shall include, without limitation, all fees,
costs and expenses of appeals.

     3.8  Titles and Subtitles. The titles of the sections and subsections of
this Agreement are for convenience of reference only and are not to be
considered in construing this Agreement.

     3.9  Counterparts. This Agreement may be executed in any number of
counterparts, each of which shall be an original, but all of which together
shall constitute one instrument.

                 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

                                      10
<PAGE>

     In Witness Whereof, the parties hereto have executed this Registration
Rights Agreement as of the date set forth in the first paragraph hereof.

COMPANY:                                     HOLDER:

IntraBiotics Pharmaceuticals, Inc.           Diversa Corporation

By:  /s/ Kenneth J. Kelley                   By:  /s/ Karin Eastham
   --------------------------------------       -------------------------------
    Kenneth J. Kelley                            Karin Eastham
    President and Chief Executive Officer        Senior Vice President, Finance
                                                 and Chief Financial Officer

                                      11
<PAGE>

                                   Exhibit C

                          Assays Assigned to Diversa

[***]

* CONFIDENTIAL TREATMENT REQUESTED

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00028-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00028-of-00352.parquet"}]]